Vertex on track for “five launches in five disease areas over a five-year period” through emerging pain and renal franchises.

Cystic fibrosis causes a buildup of mucus in the lungs that can lead to infection, and often death in children and young ...

The cost of medication was too high for thousands of CF sufferers around the world. Now a Bangladeshi company is making a generic version that will change lives ...

AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...

Boston-based Vertex Pharmaceuticals is in a dispute with Canadian officials over access to its cystic fibrosis drugs, STAT reported. The dispute focuses on three of Vertex’s drugs, Kalydeco, Orkambi ...

Vertex Pharmaceuticals Inc. reported third-quarter sales that beat analysts’ expectations as the biotech company’s mainstay cystic fibrosis treatment saw revenue growth, even as new drugs’ ...

Enlaza Therapeutics ("Enlaza" or the "Company"), the first covalent biologics platform company, today announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals ("Vertex") ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $496.45, a high estimate of $564.00, and a low estimate of $414.00. Witnessing a positive shift, the ...

In January, the Food and Drug Administration (FDA) approved Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Journavx, a non-opioid oral pain signal inhibitor for acute pain. This marked the first approval ...

Optum Rx, a pharmacy benefit manager owned by one of the country’s largest insurance companies, UnitedHealth Group, has added a new, much-anticipated pain drug to some of its commercial formularies.

Now, it’s worth noting Stock Advisor’s total average return is 968 % — a market-crushing outperformance compared to 197% for ...